As Sanofi anticipates sales of immunotherapy juggernaut Dupixent reaching a major $22 ... s first quarter conference call. Medicare and commercial coverage are at 90% and 88% respectively, Foard ...

Dupixent is an injection administered under the skin ... that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful ...

The condition is linked to Type 2 inflammation, which Dupixent helps target by blocking certain immune signaling pathways. The injection is already approved for CSU in several other countries ...

(Reuters) -The U.S. Food and Drug Administration approved the use of Sanofi and Regeneron's blockbuster drug Dupixent for patients with a type of skin condition, the two companies said on Friday.

The most common adverse reaction reported with dupilumab in all 3 CUPID trials were injection site reactions. “Dupixent is the first new targeted treatment for chronic spontaneous urticaria ...

France's Sanofi reported first-quarter profit that beat analysts' expectations on Thursday, boosted by strong demand for its ...

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the U.S. Food and Drug Administration has approved Dupixent for the treatment of adults and adolescents aged 12 years and older ...